Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
23 Apr 2024
23 Apr 2024
Historique:
revised:
11
03
2024
received:
18
10
2023
accepted:
13
03
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
23
4
2024
Statut:
aheadofprint
Résumé
Magnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long-term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long-term outcomes. Patients with CD underwent MRE 46 weeks after initiating biological treatment and were prospectively followed for 2 years. A logistic regression analysis was performed to assess the prognostic value of different radiologic findings for various predefined adverse outcomes. Of the 89 patients included, 46 (51.7%) had ≥1 adverse outcome during follow-up: 40 (44.9%) had clinical recurrence; 18 (20.2%) required surgery, 8 (9%) endoscopic balloon dilation, 12 (13.5%) hospitalization and 7 (7.8%) required corticosteroids. In the multivariate analysis, persistence of severe lesions (MaRIA ≥11) in any intestinal segment was associated with an increased risk of surgery [OR 11.6 (1.5-92.4)], of surgery and/or endoscopic balloon dilation [OR 6.3 (1.3-30.2)], and of clinical relapse [OR 4.6 (1.6-13.9)]. Penetrating lesions were associated with surgery [OR 3.4 (1.2-9.9)]. Creeping fat with hospitalization [OR 5.1 (1.1-25.0)] and corticosteroids requirement [OR 16.0 (1.2-210.0)]. The presence of complications (stricturing and/or penetrating lesions) was associated with having ≥1 adverse outcome [OR 3.35 (1.3-8.5)]. MRE findings at week-46 after initiating biological therapy can predict long-term adverse outcomes in CD. Therapeutic intervention may be required in patients with persistence of severe inflammatory lesions, CD-associated complications, or creeping fat.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Magnetic resonance enterography (MRE) depicts transmural changes in response to biological treatment for Crohn's disease (CD); however, the long-term prognostic significance of these findings is unknown. The primary objective of this study was to identify findings on MRE 46 weeks after initiating biological treatment that predict adverse long-term outcomes.
METHODS
METHODS
Patients with CD underwent MRE 46 weeks after initiating biological treatment and were prospectively followed for 2 years. A logistic regression analysis was performed to assess the prognostic value of different radiologic findings for various predefined adverse outcomes.
RESULTS
RESULTS
Of the 89 patients included, 46 (51.7%) had ≥1 adverse outcome during follow-up: 40 (44.9%) had clinical recurrence; 18 (20.2%) required surgery, 8 (9%) endoscopic balloon dilation, 12 (13.5%) hospitalization and 7 (7.8%) required corticosteroids. In the multivariate analysis, persistence of severe lesions (MaRIA ≥11) in any intestinal segment was associated with an increased risk of surgery [OR 11.6 (1.5-92.4)], of surgery and/or endoscopic balloon dilation [OR 6.3 (1.3-30.2)], and of clinical relapse [OR 4.6 (1.6-13.9)]. Penetrating lesions were associated with surgery [OR 3.4 (1.2-9.9)]. Creeping fat with hospitalization [OR 5.1 (1.1-25.0)] and corticosteroids requirement [OR 16.0 (1.2-210.0)]. The presence of complications (stricturing and/or penetrating lesions) was associated with having ≥1 adverse outcome [OR 3.35 (1.3-8.5)].
CONCLUSION
CONCLUSIONS
MRE findings at week-46 after initiating biological therapy can predict long-term adverse outcomes in CD. Therapeutic intervention may be required in patients with persistence of severe inflammatory lesions, CD-associated complications, or creeping fat.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National R & D & I Program and co-financed by the ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER)
ID : PI16/00721
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE‐II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat‐to‐target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
Guimarães LS, Greer MLC, Dillman JR, Fletcher JG. Magnetic resonance in Crohn's disease: diagnosis, disease burden, and classification. Magn Reson Imaging Clin N Am. 2020;28(1):31–44.
Panés J, Bouzas R, Chaparro M, García‐Sánchez V, Gisbert JP, Martínez De Guereñu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther. 2011;34(2):125–145.
Kucharzik T, Tielbeek J, Carter D, Taylor SA, Tolan D, Wilkens R, et al. ECCO‐ESGAR topical review on optimizing reporting for cross‐sectional imaging in inflammatory bowel disease. J Crohns Colitis. 2022;16(4):523–543.
Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn's disease. Gastroenterology. 2018;154(4):1172–1194.
Rimola J, Ordás I, Rodriguez S, García‐Bosch O, Aceituno M, Llach J, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17(8):1759–1768.
Ordás I, Rimola J, Alfaro I, Rodríguez S, Castro‐Poceiro J, Ramírez‐Morros A, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn's disease. Gastroenterology. 2019;157(2):432–439.e1.
Steward MJ, Punwani S, Proctor I, Adjei‐Gyamfi Y, Chatterjee F, Bloom S, et al. Non‐perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR‐based activity index. Eur J Radiol. 2012;81(9):2080–2088.
Rimola J, Rodriguez S, García‐Bosch O, Ordás I, Ayala E, Aceituno M, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut. 2009;58(8):1113–1120.
Hanžel J, Jairath V, Ma C, Guizzetti L, Zou G, Santillan CS, et al. Responsiveness of magnetic resonance Enterography indices for evaluation of luminal disease activity in Crohn's disease. Clin Gastroenterol Hepatol. 2022;20(11):2598–2606.
Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez‐Pérez MJ, Blanc E, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology. 2014;146:374–382.e1.
Zorzi F, Rubin DT, Cleveland NK, Monteleone G, Calabrese E. Ultrasonographic transmural healing in Crohn's disease. Am J Gastroenterol. 2023; 118(6):961–969.
Lafeuille P, Hordonneau C, Vignette J, Blayac L, Dapoigny M, Reymond M, et al. Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease. Aliment Pharmacol Ther. 2021;53(5):577–586.
Castiglione F, Imperatore N, Testa A, De Palma GD, Nardone OM, Pellegrini L, et al. One‐year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther. 2019;49(8):1026–1039.
Ma L, Li W, Zhuang N, Yang H, Liu W, Zhou W, et al. Comparison of transmural healing and mucosal healing as predictors of positive long‐term outcomes in Crohn's disease. Ther Adv Gastroenterol. 2021;14. https://doi.org/10.1177/17562848211016259
Fernandes SR, Rodrigues RV, Bernardo S, Cortez‐Pinto J, Rosa I, Da Silva JP, et al. Transmural healing is associated with improved long‐term outcomes of patients with Crohn's disease. Inflamm Bowel Dis. 2017;23(8):1403–1409.
Jauregui‐Amezaga A, Rimola J, Ordás I, Rodríguez S, Ramírez‐Morros A, Gallego M, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn's disease in the era of biologics. Gut. 2015;64(9):1397–1402.
Geyl S, Guillo L, Laurent V, D'Amico F, Danese S, Peyrin‐Biroulet L. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol. 2021;6(8):659–667.
Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T. Recent advances in clinical practice: advances in cross‐sectional imaging in inflammatory bowel disease. Gut. 2022;71(12):2587–2597.
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence‐based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohn's Colitis. 2010;4(1):7–27.
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence‐based consensus on the diagnosis and Management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383–1395.
Rimola J, Fernàndez‐Clotet A, Capozzi N, Rojas‐Farreras S, Alfaro I, Rodríguez S, et al. Pre‐treatment magnetic resonance enterography findings predict the response to TNF‐alpha inhibitors in Crohn's disease. Aliment Pharmacol Ther. 2020;52(10):1563–1573.
Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Nagahori M, Fujii T, et al. Utility of magnetic resonance enterography for small bowel endoscopic healing in patients with Crohn's disease. Am J Gastroenterol. 2018;113(2):283–294.
Holt DQ, Moore GT, Strauss BJG, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post‐operative Crohn's disease recurrence. Aliment Pharmacol Ther. 2017;45(9):1255–1264.
Mao R, Kurada S, Gordon IO, Baker ME, Gandhi N, McDonald C, et al. The mesenteric fat and intestinal muscle Interface: creeping fat influencing stricture formation in Crohn's disease. Inflamm Bowel Dis. 2019;25(3):421–426.
Gonçalves P, Magro F, Martel F. Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. Inflamm Bowel Dis. 2015;21(2):453–467.
Torres J, Mehandru S, Colombel JF, Peyrin‐Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741–1755.
Rimola J, Alfaro I, Fernández‐Clotet A, Castro‐Poceiro J, Vas D, Rodríguez S, et al. Persistent damage on magnetic resonance enterography in patients with Crohn's disease in endoscopic remission. Aliment Pharmacol Ther. 2018;48(11–12):1232–1241.
Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231(1):38–45.
Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis. 2001;7(4):306–313.